Abbott announced it has received CE Mark approval for its new, highly sensitive diagnostic test for detection of hepatitis B surface antigen.
Abbott
Abbott Launches Next-Generation XIENCE PRIME™ Drug Eluting Stent in International Markets
Abbott today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
Abbott Receives CE Mark For Company’s Next-Generation XIENCE PRIME™ Drug Eluting Stent
Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Abbott Initiates Trial of Next-Generation XIENCE PRIME™ Drug Eluting Stent
Abbott today announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company’s next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
Abbott Initiates U.S. Study of Absolute Pro™ Peripheral Stent System for Iliac Artery Disease
Abbott today announced the initiation of MOBILITY, a clinical trial studying the safety and efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in patients with iliac artery disease.
Abbott Completes Acquisition of Advanced Medical Optics
Abbott today announced that it has completed its acquisition of Advanced Medical Optics. AMO is now a wholly owned subsidiary of Abbott and has been renamed Abbott Medical Optics Inc.